多发性硬化症患者中持续性中和抗干扰素-β抗体的检测和动力学。ABIRISK 前瞻性队列研究结果。
Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study.
机构信息
Danish Multiple Sclerosis Center, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Department of Neurology, University Hospital Köln, Köln, Germany; University of Düsseldorf, Medical Faculty, Department of Neurology, Düsseldorf, Germany.
出版信息
J Neuroimmunol. 2019 Jan 15;326:19-27. doi: 10.1016/j.jneuroim.2018.11.002. Epub 2018 Nov 7.
Two validated assays, a bridging ELISA and a luciferase-based bioassay, were compared for detection of anti-drug antibodies (ADA) against interferon-beta (IFN-β) in patients with multiple sclerosis. Serum samples were tested from patients enrolled in a prospective study of 18 months. In contrast to the ELISA, when IFN-β-specific rabbit polyclonal and human monoclonal antibodies were tested, the bioassay was the more sensitive to detect IFN-β ADA in patients' sera. For clinical samples, selection of method of ELISA should be evaluated prior to the use of a multi-tiered approach. A titer threshold value is reported that may be used as a predictor for persistently positive neutralizing ADA.
两种经过验证的检测方法，桥接 ELISA 和基于荧光素酶的生物测定法，用于检测多发性硬化症患者针对干扰素-β (IFN-β) 的抗药物抗体 (ADA)。对参加为期 18 个月的前瞻性研究的患者的血清样本进行了测试。与 ELISA 相反，当测试 IFN-β 特异性兔多克隆和人单克隆抗体时，生物测定法对检测患者血清中的 IFN-β ADA 更敏感。对于临床样本，在使用多层次方法之前，应评估 ELISA 方法的选择。报告了一个滴度阈值值，可作为持续阳性中和 ADA 的预测因子。
Zotero 插件